Algert Global’s Neurocrine Biosciences NBIX Stock Holding History

Algert Global’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19,970	Closed	-$2.63M	–	1357
2026 Q1	$2.63M	Buy	19,970 +10	+0.1%	+$1.33K	0.04%	639
2025 Q4	$2.83M	Buy	19,960 +17,590	+742%	+$2.55M	0.04%	617
2025 Q3	$333K	Buy	+2,370	New	+$321K	0.01%	981
2025 Q2	–	Sell	-11,676	Closed	-$1.29M	–	1288
2025 Q1	$1.29M	Sell	11,676 -22,490	-66%	-$2.85M	0.03%	721
2024 Q4	$4.66M	Buy	34,166 +15,800	+86%	+$1.95M	0.11%	307
2024 Q3	$2.12M	Buy	+18,366	New	+$2.52M	0.06%	531
2024 Q2	–	Sell	-2,042	Closed	-$282K	–	1563
2024 Q1	$282K	Sell	2,042 -2,140	-51%	-$292K	0.01%	903
2023 Q4	$551K	Buy	4,182 +2,220	+113%	+$256K	0.02%	793
2023 Q3	$221K	Sell	1,962 -15,244	-89%	-$1.61M	0.01%	950
2023 Q2	$1.62M	Buy	+17,206	New	+$1.68M	0.07%	469

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Algert Global's NBIX Position: Q2 2026 in Review

Algert Global sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 19,970 shares — an estimated $2.63M sold.

Algert Global first reported a position in NBIX in Q2 2023 and held it in 10 quarters. The position peaked at $4.66M in Q4 2024. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Algert Global reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
Algert Global sold 19,970 Neurocrine Biosciences shares in Q2 2026, an estimated $2.63M.
Algert Global first reported a position in Neurocrine Biosciences in Q2 2023 and held it in 10 quarters.
Algert Global's Neurocrine Biosciences position peaked at $4.66M in Q4 2024.
777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.